Horby P, et al. Effect of dexamethasone inhospitalizedpatients with COVID-19: Preliminary report....
[8]Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med. 2022 Feb 10;386(6):509-520. doi: 10.1056/NEJMoa2116044 [9...
Since Paxlovid is cleared by the kidneys, dose adjustments may be required for patients with mild-to-moderate kidney disease. For patients with severe kidney disease—or who are on dialysis—or those with severe liver disease, Paxlovid is not recommended; the levels of the drug can become too...
Since Paxlovid is cleared by the kidneys, dose adjustments may be required for patients with mild-to-moderate kidney disease. For patients with severe kidney disease—or who are on dialysis—or those with severe liver disease, Paxlovid is not recommended; the levels of the drug can become too...
Paxlovid(奈玛特韦片/利托那韦片组合包装)是一种用于治疗新型冠状病毒肺炎 COVID-19 的复方药物,据《新英格兰医学杂志》及官方数据报道:对于已经出现症状、且未接受疫苗接种的门诊新冠病毒感染患者,与安慰剂组相比,其可使患者进展为重症的发生率降低 89%,且试验期间未发现严重的安全性问题[4][5]。
Paxlovid是美国辉瑞公司生产的抗病毒药物，于2021年底获得美国食品药品监督管理局（FDA）紧急使用授权，...
[6] COVID-19 Supplemental Clinical Guidance #4: Nirmatrelvir/Ritonavir (Paxlovid) Use in Patients With Advanced Chronic Kidney Disease and Patients on Dialysis with COVID-19. Ontario renal network, April 13, 2022 [7] 日本厚生省. 新型冠状病毒肺炎治疗手册第 8.1 版 [M].2022.10:10-15 ...
[6] COVID-19 Supplemental Clinical Guidance #4: Nirmatrelvir/Ritonavir (Paxlovid) Use in Patients With Advanced Chronic Kidney Disease and Patients on Dialysis with COVID-19. Ontario renal network, April 13, 2022 [7]...
Paxlovid(奈玛特韦片/利托那韦片组合包装)是一种用于治疗新型冠状病毒肺炎 COVID-19 的复方药物,据《新英格兰医学杂志》及官方数据报道:对于已经出现症状、且未接受疫苗接种的门诊新冠病毒感染患者,与安慰剂组相比,其可使患者进展为重症的发生率降低 89%,且试验期间未发现严重的安全性问题[4][5]。
[6] COVID-19 Supplemental Clinical Guidance #4: Nirmatrelvir/Ritonavir (Paxlovid) Use in Patients With Advanced Chronic Kidney Disease and Patients on Dialysis with COVID-19. Ontario renal network, April 13, 2022 [7] 日本厚生省. 新型冠状病毒肺炎治疗手册第 8.1 版 [M].2022.10:10-15 ...